187 related articles for article (PubMed ID: 11358843)
1. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.
Kamada M; Suzuki K; Kato Y; Okuda H; Shuin T
Cancer Res; 2001 May; 61(10):4184-9. PubMed ID: 11358843
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
3. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions.
Esteban-Barragán MA; Avila P; Alvarez-Tejado M; Gutiérrez MD; García-Pardo A; Sánchez-Madrid F; Landázuri MO
Cancer Res; 2002 May; 62(10):2929-36. PubMed ID: 12019174
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
5. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Bindra RS; Vasselli JR; Stearman R; Linehan WM; Klausner RD
Cancer Res; 2002 Jun; 62(11):3014-9. PubMed ID: 12036906
[TBL] [Abstract][Full Text] [Related]
6. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
7. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
8. von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.
Turcotte S; Desrosiers RR; Brand G; Béliveau R
Int J Cancer; 2004 Dec; 112(5):777-86. PubMed ID: 15386385
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
10. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
12. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion.
Datta K; Sundberg C; Karumanchi SA; Mukhopadhyay D
Cancer Res; 2001 Mar; 61(5):1768-75. PubMed ID: 11280720
[TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
Kondo K; Klco J; Nakamura E; Lechpammer M; Kaelin WG
Cancer Cell; 2002 Apr; 1(3):237-46. PubMed ID: 12086860
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
18. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ
Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063
[TBL] [Abstract][Full Text] [Related]
19. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
Kuehn EW; Walz G; Benzing T
Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
[TBL] [Abstract][Full Text] [Related]
20. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
